Convalife Pharmaceuticals key facts
as of Oct 2026- Researcher and developer of innovative drugs focused on oncology treatments.
- Convalife Pharmaceuticals is valued at approximately $444.6M as of Oct 2026 (last reported valuation).
- It has raised $59.8M; the latest was IPO in Aug 2025.
- Notable investors include Optics Valley Financial Holdings Group, Fujian Shangrun Investment Management, Beijing Chuangye Letu Technology Group, Chengrong Investment, Hiway Capital — 12 tracked in total.
- Status: In IPO Registration.
Convalife Pharmaceuticals's last reported valuation, Jul 2025. Nothing priced has surfaced since.
- ·The complete investor list: 12 names
- ·Watch Convalife Pharmaceuticals: the Monday email on marks, rounds and moves
Convalife Pharmaceuticals funding rounds
No funding rounds for Convalife Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Convalife Pharmaceuticals
12+Convalife Pharmaceuticals valuation
Convalife Pharmaceuticals's last reported valuation was $445 million in Jul 2025. No priced round, secondary trade or fund mark has surfaced since.
Convalife Pharmaceuticals investors
12 investors are on record for Convalife Pharmaceuticals, including Optics Valley Financial Holdings Group, Fujian Shangrun Investment Management, Beijing Chuangye Letu Technology Group and Chengrong Investment.
About Convalife Pharmaceuticals
Researcher and developer of innovative drugs focused on oncology treatments. The company focuses on antibody biopharmaceuticals and small molecule drug in tumor disease field, aiming to provide cancer patients with treatment options.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2015
- Employees
- 67
- Website
- convalife.com/
- Ownership
- In IPO Registration
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.